Estabrook Capital Management’s Editas Medicine EDIT Stock Holding History

Estabrook Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13	Closed	-$115	–	403
2022 Q4	$115	Hold	13	–	–	﹤0.01%	416
2022 Q3	$159	Hold	13	–	–	﹤0.01%	415
2022 Q2	$154	Hold	13	–	–	﹤0.01%	418
2022 Q1	$247	Hold	13	–	–	﹤0.01%	411
2021 Q4	$345	Hold	13	–	–	﹤0.01%	437
2021 Q3	$534	Hold	13	–	–	﹤0.01%	309
2021 Q2	$736	Hold	13	–	–	﹤0.01%	307
2021 Q1	$546	Hold	13	–	–	﹤0.01%	312
2020 Q4	$911	Hold	13	–	–	﹤0.01%	318
2020 Q3	$365	Hold	13	–	–	﹤0.01%	313
2020 Q2	$385	Hold	13	–	–	﹤0.01%	324
2020 Q1	$258	Hold	13	–	–	﹤0.01%	324
2019 Q4	$385	Buy	+13	New	+$325	﹤0.01%	331

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Estabrook Capital Management's EDIT Position: Q1 2023 in Review

Estabrook Capital Management sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 13 shares — an estimated $115 sold.

Estabrook Capital Management first reported a position in EDIT in Q4 2019 and held it in 13 quarters. The position peaked at $911 in Q4 2020. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

Estabrook Capital Management reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
Estabrook Capital Management sold 13 Editas Medicine shares in Q1 2023, an estimated $115.
Estabrook Capital Management first reported a position in Editas Medicine in Q4 2019 and held it in 13 quarters.
Estabrook Capital Management's Editas Medicine position peaked at $911 in Q4 2020.
234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on Estabrook Capital Management's 13F filing for Q1 2023, filed 12 May 2023.